[1]NOTE: As
provided in LFC policy, this report is intended for use by the standing
finance committees of the legislature. The Legislative Finance
Committee does not assume responsibility for the accuracy of the information
in this report when used in any other situation.
Only the most recent FIR
version, excluding attachments, is available on the Intranet. Previously issued FIRs and attachments may
be obtained from the LFC office in Suite 101 of the State Capitol Building
North.
SPONSOR: |
Maes |
DATE TYPED: |
01/22/02 |
HB |
|
||
SHORT TITLE: |
Compassionate Use Medical Cannabis Act |
SB |
8 |
||||
|
ANALYST: |
Esquibel |
|||||
APPROPRIATION
Appropriation Contained |
Estimated Additional Impact |
Recurring or Non-Rec |
Fund Affected |
||
FY02 |
FY03 |
FY02 |
FY03 |
|
|
|
N/A |
|
|
|
|
(Parenthesis
( ) Indicate Expenditure Decreases)
LFC Files
Department of Health (DOH)
Public Defender Department (PDD)
Attorney General (AG)
Administrative Office of the Courts (AOC)
SUMMARY
Senate Bill 8 proposes
to enact the Compassionate Use Medical Cannabis Act, and amends and repeals
certain provisions of the Controlled Substances Act. Key provisions of the bill include:
1. The establishment of the
“Compassionate Use Medical Cannabis Act,” the purpose of the act being
to allow the beneficial use of marijuana in treating certain medical conditions
based on findings that:
·
Marijuana
is a medically valuable treatment for a variety of medical conditions.
·
State
law should make a distinction between medical and non-medical use of marijuana.
·
Practitioners
should not be penalized for including marijuana as a treatment option for patients
·
Patients
should not be penalized for acting on a practitioner’s advice to use marijuana
as a treatment option.
Senate Bill 8 – Page 8
2. The act establishes a
program within the Department of Health to administer a medical use of
marijuana program pursuant to the Compassionate Use Medical Cannabis Act.
Provisions of the program include the promulgation of rules by the Secretary of
Health, the establishment of requirements and procedures for program
qualification and participation including certification of patients and
requirements of other participants, and creates a picture identification card
for all persons certified to participate in any aspect of the medical cannabis
program.
3. Section 3, Definitions, defines
“debilitating medical condition” to mean:
·
Cancer
·
Human
immunodeficiency virus or acquired immune deficiency syndrome
·
Glaucoma
· Neuromuscular conditions
that include spasticity or seizures
· Other debilitating
illnesses or conditions for which marijuana has a therapeutic benefit and
that the department designates by adopted rule as being a debilitating medical
condition.
4. Relieves
patients and their caregivers certified with the program or other persons from
arrest or criminal prosecution for possession (but does not include
distributing, cultivation or selling) of marijuana in amounts not in excess of
what is reasonably necessary for uninterrupted medical
treatment. Includes prohibitions,
restrictions and limitations on the medical use of marijuana that do not
relieve the certified patient, or primary caregiver from liability or criminal
prosecution for activities not authorized the Compassionate Use Medical Cannabis Act.
5. Allows participation of
a minor under the age of eighteen (18) in the program with parental consent.
6. Places prohibitions,
restrictions and limitations on the medical use of marijuana that do not
relieve the certified patient from liability or criminal prosecution including
operation of a vehicle while under the influence of marijuana and possession in
certain public places.
7. Establishes fraudulent
representation to law enforcement about participation in the program as a crime
punishable as a petty misdemeanor.
8. Amends the Controlled
Substances Act considers and moves marijuana, tetrahydrocannabinols or their
chemical derivatives from Schedule I to Schedule II substances only for the purposes
of the medical use of marijuana program pursuant to the Compassionate Use of
Medical Cannabis Act. In all other
circumstances, marijuana remains a Schedule I substance under the act.
9. Specifies the Department
of Health as the regulatory authority for methadone use in rehabilitation programs.
Significant Issues
Arguments for the
medical use of marijuana include:
1. There is a wealth of
literature available concerning medical conditions that may respond to the
therapeutic use of marijuana under controlled circumstances. Such conditions include “wasting syndrome”,
nausea, and other side effects of AIDS and chemotherapy; glaucoma, multiple
sclerosis, and Chron’s disease.
2. The National Institutes
of Health has issued a report reviewing the scientific data concerning the
potential therapeutic uses for marijuana and the need for and feasibility of,
additional research. The findings of this report include:
·
Marijuana
has potential therapeutic efficacy in the following clinical medical
conditions: analgesia, neurological and movement disorders, nausea and vomiting
associated with cancer chemotherapy, glaucoma, cachexia, and appetite
stimulation in patients with AIDS or cancer.
·
It
is difficult to compare marijuana with products that have received regulatory
approval under more rigorous experimental conditions than those previously
conducted on marijuana.
·
More
and better clinical trials and studies would be needed.
Arguments against the
medical use of marijuana include:
1. Marijuana is not a pure
substance, is unstable, and is a varying and complex mixture of over 400
chemicals.
2. When smoked, marijuana
produces over 2,000 chemicals including, hydrogen cyanide, ammonia, carbon
monoxide, acetaldehyde, acetone, phenol, cresol, naphtalene, and other well
known carcinogens, many in higher concentrations than in tobacco smoke.
3. Marijuana causes cancer of the lungs, mouth,
lip and tongue.
4. The National Institute of Allergy and
Infectious Disease reports that the many carcinogens in marijuana smoke would
be a health hazard for patients with compromised immune systems.
5. Marijuana is a Schedule I controlled substance determined by the FDA to be highly addictive with no medicinal value.
6. Studies have shown that HIV positive smokers
progress to full blown AIDS twice as fast as nonsmokers. (AIDS Weekly)
7. According to the American Psychiatric
Association, Diagnostic and Statistical Manual of Mental Disorders (DSM IV),
marijuana causes mental disorders such as schizophrenia and other psychoses,
depression, panic attacks, hallucinations, paranoia, hostility, depersonalization,
flashbacks, decreased cognitive performance, disconnected thought delusions and
impaired memory.
8. The main psychoactive ingredient in marijuana
(THC) is already legally available as a Schedule II controlled substance.
9. The quality control of marijuana is difficult
to standardize and regulate.
Senate Bill 8 – Page 4
The Department of Public
Safety anticipates that there would be an administrative and fiscal impact on
all law enforcement and the criminal justice system because a new crime
involving false reporting of participation in the Act would have been
created. Creation of new crimes creates
a fiscal impact on all aspects of the criminal justice system. Additionally, the legislation as proposed
exempts certain people from prosecution which could entail training law
enforcement officers and prosecutors as to how to apply the provisions of the
Act in making decisions as to whether individuals should be arrested and/or
prosecuted.
The Board of Nursing
indicates that the bill could increase the cost of care if all practitioners
who have prescriptive authority are not included in the provisions of the
bill. This would include not just
physicians are currently prescribed in the bill, but also doctors of oriental
medicine, dentists, physician assistants, certified nurse practitioners,
clinical nurse specialists and certified nurse midwives.
ADMINISTRATIVE
IMPLICATIONS
The bill includes no
appropriation to DOH to allow it to implement the medical use of marijuana
program.
Repealing the state laws
criminalizing marijuana places the enforcement burden entirely on the federal
government.
It may be necessary to
amend certain sections of the Medical Practice Act in order to fully offer
physicians or other providers prescribing marijuana for therapeutic use the
protections offered under the Act.
TECHNICAL ISSUES
·
HPC
indicates Section 6, Lawful Activities, Part C includes relief from arrest or
prosecution for persons registered by the program who may be “selling”
marijuana. The bill makes no other
provisional reference under which the sale of marijuana is legal, necessary,
conditional or regulated. Nor does the
bill specify that DOH or any other authority shall establish rules and regulations
under which persons approved by DOH may legally produce, possess, distribute,
cultivate or sell marijuana for the purposes of the Compassionate Use Medical
Cannabis Act.
·
The
Act does not make provisions for the establishment of rules or regulations by
DOH or any other regulatory authority regarding production, possession,
distribution, cultivation or sale of marijuana for the purposes of the
Compassionate Use Medical Cannabis Act.
Senate Bill 8 – Page 5
·
The
Act does not make provisions for the taxation of marijuana distributors.
·
The
Act does not make provisions for obtaining or distributing marijuana to
patients for use in the program beyond decriminalizing producing for patients
or others registered with the program.
Federal regulation of therapeutic research programs is very specific as
to where and how marijuana may be obtained and distributed for use in a state
program. Issues of distributing
marijuana to be used for medicinal purposes to be considered are:
1. Legal sources of marijuana for research
purposes include:
·
Receiving
it from the National Institute on Drug Abuse (NIDA);
·
Importing
it from specific sources with permission from the DEA;
·
DEA
permission to cultivate it; and
·
Using
confiscated marijuana supplied by the state police.
2. Using marijuana confiscated by state police for the purposes of a medicinal use of marijuana program requires that the marijuana must be tested to meet federal requirements on impurity, which is cost prohibitive.
3. Obtaining or
distributing marijuana outside of the currently approved therapeutic research
program puts NM in violation of federal law.
4. The state of Washington
has appropriated funds for the purpose of researching tamper-free means of
cultivating marijuana for medicinal purposes with the intent of applying to the
federal government to become an alternative source of marijuana for research
purposes.
5. The State Department of Education recommends
including language in Section 8B that clearly prohibits the compassionate use
of medical marijuana at all school-sponsored activities, including those events
that may occur in a non-public place such as booster club pre-game events.
OTHER SUBSTANTIVE ISSUES
Medical marijuana use
laws in other states vary. Those states
that have passed laws related to the medical use of marijuana have done so with
the same intent and findings provided in this bill. Sufficient scientific evidence exists to cause 35 states to enact
favorable laws addressing the medical use of marijuana. Issues from the experiences of these states
that should be noted are:
·
California,
Arizona, Montana, Louisiana, Tennessee, Virginia, Ohio, Iowa, Wisconsin, Vermont,
and the District of Columbia have passed laws providing for medical use of
marijuana outside of the federally approved therapeutic research program. While
upheld by a U.S. District Court in California, the U.S. Supreme Court has effectively
overturned California’s 1996 passed ballot initiative, Proposition 215, barring
the distribution of
Senate Bill 8 – Page 6
marijuana for medical
purposes, but did not address the issue of patients cultivating marijuana for
their own use.
·
Laws
in Arizona and Louisiana allow physicians to prescribe Schedule I controlled substances
under rules promulgated by the state.
·
Montana
and District of Columbia laws would automatically reschedule THC and marijuana
to Schedule II if the federal government authorizes the prescription or
administration of these substances.
·
5
states including California, Michigan, Missouri, New Hampshire and New Mexico have
passed non-binding resolutions urging the federal government to allow doctors
to prescribe marijuana.
·
9
states including Oregon, Nevada, Colorado, Alaska and Florida have repealed
medical marijuana laws.
·
15
states, among them Hawaii, Idaho, Utah, Wyoming, and Mississippi have never had
medical use laws of any kind.
POSSIBLE QUESTIONS
1. Will legal medical use of marijuana impact
the perception of the state as a tourism destination?
2. Would passage of the bill necessitate the
need for stronger substance abuse education, including the potential for abuse
by program participants and for those who are dispensing the marijuana?
3. Will the program address the potential for
victimization of an individual with a developmental disability or dual diagnosis
participating in the program?
4. Why dismantle the Lynn Pierson Therapeutic
Research Program currently allowed for under the Controlled Substances
Therapeutic Act given that this program has already met federal regulations and
secured required permissions from the Drug Enforcement Agency and the Food and
Drug Administration for prescription and distribution of marijuana for
therapeutic research? Repealing the
Controlled Substances Therapeutic Act rather than amending provisions of the
existing program may require new application for the required permits and licenses.
5. During the 2001 Legislature, the Senate
Floor four times amended the Senate Public Affairs Committee substitute for
Senate Bill 319 (Compassionate Use of Medical Marijuana Act) as amended by
Senate Judiciary Committee to do the following:
Senate Bill 8 – Page 7
·
Stipulate
that DOH’s rulemaking for the program be in accordance with federal law and
regulations.
·
Allow
for the issuance of temporary certification to participate in the medical
cannabis program between July 1, 2001 and the effective date of the
promulgation of the program’s rules by DOH.
This section is repealed 30 days after the program’s rules are
promulgated by DOH.
·
Stipulate
that if a person approved to participate in any aspect of the program conveys
or transfers cannabis to an uncertified person, they shall be not be able to
participate in the program and be subject to arrest, prosecution and civil or
criminal penalties as allowed for under the law.
·
Specify
that DOH must ensure the production of the cannabis is secure, and that the producer
provide a regular inventory of the product.
Why
does SB8 not provide for any of these provisions?
6. During the 2001 Legislature, the Senate Judiciary Committee amendments to the Senate Public Affairs Committee substitute for Senate Bill 319 (Compassionate Use of Medical Marijuana Act) defined “cannabis” to mean any derivative of the marijuana plant; and had provisions for an advisory board composed of nine practitioners nominated by the NM Medical Society and submitted to the Secretary of Health for approval by the NM Senate. Why were none of these provisions included in SB8?
RAE/ar
[1]Begin typing on the * in replace mode. Do not add or delete spaces.